Skip to main content
. 2024 Jan 9;11(11):2302916. doi: 10.1002/advs.202302916

Figure 6.

Figure 6

AURKB regulates NFAT5‐AQP4 signaling pathway in astrocytes. A1) Aqp4 mRNA expression in the SDH of CCI rats after daily i.t. administration of AURKB inhibitor AZD1152. CCI versus sham, ***p < 0.001, CCI+ AZD1152 versus CCI+ Vehicle, ***p < 0.001, n = 6, one‐way ANOVA followed by Tukey's multiple comparison test. A2) AQP4 protein expression in the SDH of CCI rats after daily i.t. administration of AURKB inhibitor AZD1152. CCI versus sham, *p < 0.05, CCI + AZD1152 versus CCI + Vehicle, **p < 0.01, n = 4, one‐way ANOVA followed by Tukey's multiple comparison test. B1) Experimental procedure involved the overexpression of AURKB in CTX‐TNA2 cell line, followed by subsequent administration of the AURKB inhibitor AZD1152 or NFAT5 inhibitor KRN2. B2) The AURKB protein level in the LV‐Aurkb transfected CTX‐TNA2 cell line. LV‐Aurkb versus LV‐NC, **p < 0.01, n = 6, one‐way ANOVA followed by Tukey's multiple comparison test. C1‐C2) The Nfat5 mRNA and protein levels in the LV‐Aurkb transfected CTX‐TNA2 cells with AURKB inhibitor AZD1152 treatment for 24 h. Control versus LV‐Aurkb, *p < 0.05, LV‐Aurkb + Vehicle versus LV‐Aurkb + AZD1152, **p < 0.01, n = 4, one‐way ANOVA followed by Tukey's multiple comparison test. C3) The AQP4 protein levels in the LV‐Aurkb transfected CTX‐TNA2 cells administration with AURKB inhibitor AZD1152 treatment for 24 h. Control versus LV‐Aurkb, *p<0.05, LV‐Aurkb + Vehicle versus LV‐Aurkb + AZD1152, ***p < 0.001, n = 6, one‐way ANOVA followed by Tukey's multiple comparison test. D) The AQP4 protein levels in the LV‐Aurkb transfected CTX‐TNA2 cells administration with NFAT5 inhibitor KRN2 treatment for 24 h. Control versus LV‐Aurkb, *p<0.05, LV‐Aurkb + Vehicle versus LV‐Aurkb + KRN2, *p < 0.05, n = 6, one‐way ANOVA followed by Tukey's multiple comparison test. E) NFAT5 protein level in cytoplasm and nucleus of AURKB overexpressed CTX‐TNA2 cells, followed with administered AURKB inhibitor AZD1152. Control versus LV‐Aurkb, **p<0.01, LV‐Aurkb + Vehicle versus LV‐Aurkb + AZD1152, ***p < 0.001, n = 4, one‐way ANOVA followed by Tukey's multiple comparison test.